SABS vs VTRS
SABS: SAB Biotherapeutics is developing a platform of transchromosomic cattle to produce fully human, high-potency polyclonal antibodies to treat autoimmune diseases like Type 1 Diabetes. VTRS: Viatris is a global healthcare company providing a broad range of high-quality, affordable medicines across both developed and emerging markets.
Side-by-side fundamentals
| Metric | SABS | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.89 | $17.44 | |
| Market cap as of 2026-08-03 (share count; price 2026-10-08) | $263M | $20.0B | |
| Net margin FY2025, SEC XBRL | n/a | -24.6% | |
| Gross margin FY2025, SEC XBRL | n/a | +35.1% | |
| Operating margin FY2025, SEC XBRL | n/a | -18.6% | |
| ROE FY2025, SEC XBRL | +8.8% | -23.9% | SABS higher |
| ROA FY2025, SEC XBRL | +7.7% | -9.5% | SABS higher |
| Debt / equity as of 2026-09-02 | 0.01 | 0.94 | SABS lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +4.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -4.2% | |
| Dividend yield as of 2026-09-02 | n/a | +2.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | VTRS higher |
| Beta as of 2026-09-02 | 0.90 | 0.75 | |
| 1-year return as of 2026-10-08 close | +23.5% | +74.9% | VTRS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.